宣达散治疗便秘肝郁气滞证的临床研究  

Xuanda Powder in Treating Constipation with Liver Qi Depression Syndrome

作　　者：姚宏健 潘慧[2] 张相安[2] YAO Hongjian;PAN Hui;ZHANG Xiangan(Yellow River Central Hospital,Zhengzhou Henan China 450000;The First Affiliated Hospital to Henan University of Chinese Medicine,Zhengzhou Henan China 450000)

机构地区：[1]黄河中心医院,河南郑州450000 [2]河南中医药大学第一附属医院,河南郑州450000

出　　处：《中医学报》2024年第10期2251-2255,共5页Acta Chinese Medicine

基　　金：河南中医药科学研究专项课题项目(2022JDZX010)。

摘　　要：目的:观察宣达散治疗便秘肝郁气滞证的临床疗效。方法:70例便秘肝郁气滞证患者随机平均分为治疗组和对照组。治疗组给予宣达散口服治疗,对照组给予聚乙二醇口服治疗。治疗后,比较两组患者生活质量(patient-centered assessment of constipation quality of life,PAC-QOL)评分,血清5-羟色胺(5-hydroxytryptamine,5-HT)、胃动素(motilin,MTL)、血清P物质(substance P,SP)水平,临床疗效和不良反应发生率。结果:(1)观察组有效率为97.14%(34/35),对照组为83.33%(25/35),两组比较,差异有统计学意义(P<0.05)。(2)治疗后,治疗组患者便秘症状评分分别为:大便干结(1.23±0.43)分、排便不畅(0.86±0.36)分、排便时间(0.94±0.48)分、排便不尽(0.88±0.55)分,均低于同期对照组(P<0.05)。(3)治疗后,治疗组中医证候评分分别为:大便干结(0.83±0.51)分、排便不畅(0.91±0.51)分、腹胀腹痛(1.20±0.47)分、肠鸣矢气(0.86±0.49)分、心胸闷胀(0.77±0.49)分、嗳气频发(1.00±0.49)分,均低于同期对照组(P<0.05)。(4)治疗后,治疗组PAC-QOL评分为(24.54±3.63)分,低于同期对照组(P<0.05)。(5)治疗后,治疗组患者血清5-HT为(102.36±10.64)ng·L^(-1)、SP为(39.56±4.36)ng·L^(-1)、MTL为(285.63±30.67)ng·L^(-1),均高于同期对照组(P<0.05)。(6)治疗过程中两组均无不良事件发生。结论:宣达散可有效改善肝郁气滞证患者便秘症状和中医证候,并改善患者PAC-QOL评分,调节血清递质水平。Objective:To observe the clinical efficacy of Xuanda Powder in treatment of constipation and liver stagnation syndrome.Methods:A total of 70 patients with constipation and liver stagnation syndrome were randomly divided into treatment group and control group.The treatment group was treated with Xuanda Powder oral therapy,and the control group was given oral treatment with polyethylene glycol.After treatment,the Patient-Centered Assessment of Constipation Quality of Life(PAC-QOL)score,serum levels of 5-hydroxytryptamine(5-HT),motilin(MTL)and serum substance P(SP),clinical efficacy and incidence of adverse reactions were compared between the two groups.Results:(1)The effective rate of the observation group was 97.14%(34/35)and that of the control group was 83.33%(25/35),and the difference between the two groups was statistically significant(P<0.05).(2)After treatment,the scores of constipation symptoms in the treatment group were(1.23±0.43),poor defecation(0.86±0.36),defecation time(0.94±0.48)and incomplete defecation(0.88±0.55),which were significantly lower than those in the control group(P<0.05).(3)After treatment,the scores of dry stools(0.83±0.51),poor defecation(0.91±0.51),abdominal distension and abdominal pain(1.20±0.47),bowel sound and sagittal Qi(0.86±0.49),cardiothoracic distension(0.77±0.49)and frequent belching(1.00±0.49),in the TCM syndrome in the treatment group were significantly lower than those in the control group(P<0.05).(4)After treatment,the PAC-QOL score of the treatment group was(24.54±3.63),which was significantly lower than that of the control group(P<0.05).(5)After treatment,the serum 5-HT(102.36±10.64)ng·L^(-1),SP(39.56±4.36)ng·L^(-1) and MTL(285.63±30.67)ng·L^(-1),of the patients in the treatment group were higher than those in the control group(P<0.05).(6)There were no adverse events in either group during the treatment.Conclusion:Xuanda Powder can effectively improve the symptoms of constipation and TCM syndrome in patients with liver stagnation and Qi stagnation synd

关 键 词：便秘 肝郁气滞证 宣达散 神经递质 

分 类 号：R259.746.2[医药卫生—中西医结合]